Sponsored by
NuvOx Pharma is a company developing a new drug called NanO2. They have a currently recruiting Phase 2b trial called RESTORE, which is testing NanO2 together with standard of care for newly diagnosed glioblastoma. NanO2 was developed based on technology similar to ultrasound contrast agents, but modified to carry and deliver oxygen. The drug is meant to reverse tumor hypoxia, a condition that hinders the effectiveness of radiation and chemotherapy. The study investigators recently published two new journal articles, one to explain how NanO2 works and the other to describe the design and rationale for the Phase 2b clinical trial.